131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Active, not recruiting · NCT05450744 · Registry updated 2026-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-08-13 | NCT05450744 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Telix Pharmaceuticals (Innovations) Pty Limited | 11 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Gold Coast University Hospital | Gold Coast | Australia | 3 |
| Institut für Nuklearmedizin und Endokrinologie | Linz | Austria | 1 |
| Olivia Newton John Cancer Research Institute/Austin Health | Melbourne | Australia | 1 |
| Royal Adelaide Hospital | Adelaide | Australia | 10 |
| UNMC Utrecht | Utrecht | Netherlands | 1 |